 |
Journal articles
Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.
Philippe Pourquier
1
Christopher Gioffre
Glenda Kohlhagen
Yoshimasa Urasaki
François Goldwasser
2
Lary Hertel
Shuyuan Yu
Richard Pon
William Gmeiner
Yves Pommier
3
Philippe Pourquier 1
Author IdHAL : philippe-pourquier ORCID : https://orcid.org/0000-0001-5326-3005
Christopher Gioffre
Author
Glenda Kohlhagen
Author
Yoshimasa Urasaki
Author
William Gmeiner
Author
Yves Pommier 3
Author
1
Signalisation et Mecanismes Moleculaires de l'Apoptose (Instit Europeen de Chimie et Biologie 2, Rue Robert Escarpit 33600 PESSAC - France)
- Université Bordeaux Segalen - Bordeaux 2 (146 rue Léo Saignat - 33076 Bordeaux cedex - France)
- INSERM - Institut National de la Santé et de la Recherche Médicale : E347 (101, rue de Tolbiac, 75013 Paris - France)
2
Service de Cancérologie Médicale [AP-HP Cochin] (27 Rue du Faubourg Saint-Jacques, 75014 Paris - France)
- Hôpital Cochin [AP-HP] (27 Rue du Faubourg Saint-Jacques 75014 Paris - France)
3
Laboratory of Molecular Pharmacology (National Cancer Institute Bldg. 37, Room 4E28 37 Convent Drive MSC 4255 Bethesda, MD 20892-4255 - France)
- NIH - National Institutes of Health [Bethesda] (9000 Rockville Pike, Bethesda, Maryland 20892 - United States)
- NCI-NIH - National Cancer Institute [Bethesda] (BG 9609 MSC 9760, 9609 Medical Center Drive, Bethesda, MD 20892-9760 - United States)
- NIH - National Institutes of Health [Bethesda] (9000 Rockville Pike, Bethesda, Maryland 20892 - United States)
Abstract : Gemcitabine-containing regimens are among standard therapies for the treatment of advanced non-small cell lung,pancreatic, or bladder cancers. Gemcitabine is a nucleoside analogue and its cytotoxicity is correlated with incorporation into genomic DNA and concomitant inhibition of DNA synthesis. However, it is still unclear by which mechanism(s) gemcitabine incorporation leads to cell death.
Document type :
Journal articles
Domain :
Complete list of metadata
https://www.hal.inserm.fr/inserm-02438313
Contributor : Philippe Pourquier Connect in order to contact the contributor
Submitted on : Tuesday, January 14, 2020 - 10:54:27 AM
Last modification on : Wednesday, May 26, 2021 - 7:56:03 PM
Contributor : Philippe Pourquier Connect in order to contact the contributor
Submitted on : Tuesday, January 14, 2020 - 10:54:27 AM
Last modification on : Wednesday, May 26, 2021 - 7:56:03 PM
Identifiers
- HAL Id : inserm-02438313, version 1
- PUBMED : 12171875
Collections
Citation
Philippe Pourquier, Christopher Gioffre, Glenda Kohlhagen, Yoshimasa Urasaki, François Goldwasser, et al.. Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.. Clinical Cancer Research, American Association for Cancer Research, 2002, 8 (8), pp.2499-504. ⟨inserm-02438313⟩
Metrics
Record views